Mar 6, 2026 07:45AM

Jan 7, 2026 04:06PM

Jan 7, 2026 04:00PM

Dec 17, 2025 04:05PM

Dec 17, 2025 04:05PM

Dec 12, 2025 10:47AM

Nov 19, 2025 09:45AM Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B

Sep 16, 2025 07:00AM

Sep 16, 2025 07:00AM

Aug 13, 2025 04:05PM

Jul 9, 2025 08:00AM

Mar 20, 2025 04:05PM

Jan 7, 2025 07:04AM

Jan 7, 2025 07:00AM Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms

Dec 17, 2024 08:00AM

Dec 12, 2024 08:00AM

Dec 12, 2024 08:00AM

Nov 13, 2024 04:05PM

Oct 15, 2024 08:01AM

Oct 15, 2024 08:00AM

Oct 15, 2024 08:00AM Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

Sep 12, 2024 04:06PM

Sep 12, 2024 04:05PM

Aug 6, 2024 04:05PM

Jul 31, 2024 04:05PM

May 7, 2024 04:05PM

Mar 6, 2024 08:00AM

Mar 1, 2024 08:00AM Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 20, 2024 08:00AM

Feb 20, 2024 08:00AM

Dec 12, 2023 08:00AM

Dec 12, 2023 08:00AM

Mar 6, 2023 04:05PM

Mar 6, 2023 04:05PM

Sep 30, 2022 06:52AM Immuneering Corporation (IMRX) Announces FDA Cleared IND for Phase 1/2a Trial of IMM-1-104

Sep 30, 2022 06:50AM

Sep 30, 2022 06:50AM

Sep 2, 2022 08:09AM

Sep 2, 2022 08:09AM

Sep 2, 2022 08:09AM

Mar 31, 2022 04:05PM

Mar 10, 2022 06:34AM Immuneering Corporation (IMRX) Reports Q4 Earnings, Provides Business Updates

Mar 10, 2022 06:30AM

Mar 10, 2022 06:30AM

Jan 18, 2022 06:50AM

Jan 18, 2022 06:50AM

Jan 18, 2022 06:50AM

Jan 6, 2022 04:14PM

Jan 6, 2022 04:10PM Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event

Jan 6, 2022 04:10PM

322,084 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All